Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

American Journal of Health-System Pharmacy

Volumn 71, Issue 5, 2014, Pages 386-393

  Stone, Lowell E ^a   Skelley, Jessica W ^a   Kyle, Jeffrey A ^a   Elmore, Lindsey K ^a  

^a SAMFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; TROPANE DERIVATIVE;

BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; METERED DOSE INHALER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; UNITED STATES; ADULT; AGED; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TROPANES;

EID: 84907219714     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130077     Document Type: Review

References (24)

1. Tudorza Pressair package insert. Forest Pharmaceuticals, Inc., St. Louis, MO; July 2012. www.frx.com/pi/tudorza-pi.pdf (accessed 2013 Nov 5).
2. World Health Organization. World heath report. www.who.int/mediacentre/factsheets/fs315/en/ (accessed 2012 Dec 17).
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. www.goldcopd.org/guidelines-global-strategy-for-diagnosis- management.html (accessed 2012 Dec 17).
4. Tiotropium. In: Micromedex 2.0 [Internet database]. Ann Arbor, MI: Truven Health Analytics Inc. (accessed 2012 Dec 17).
5. Almirall S.A. Almirall's aclidinium recommended for approval in Europe to treat COPD. www.almirall.com/webcorp2/cda/comunicacion-detalle-noticia.jsp?id=1671 (accessed 2012 Dec 17).
6. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006; 7:73.
7. Gavalda A, Miralpeix M, Ramos I et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009; 331:740-51.
8. Schmid K, Pascual S, Garcia Gil E et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther. 2010; 32:1798-812.
9. Lasseter K, Dilzer S, Jansat JM et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther. 2012; 25:193-9.
10. Ortiz S, Flach S, Caracta C et al. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol. 2012; 52:819-27.
11. Alberti J, Martinet A, Sentellas S, Salva M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010; 38:1202-10.
12. Chanez P, Burge PS, Dahl R et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010; 23:15-21.
13. Jones PW, Rennard SI, Agusti A et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011; 12:55.
14. Fuhr R, Magnussen H, Sarem K et al. Efficacy of aclidinium bromide 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012; 141:745-52.
15. Singh D, Magnussen H, Kirsten A et al. A randomized, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012; 25:248-53.
16. Kerwin EM, D'Urzo AD, Gelb AF et al. ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9:90-101.
17. Jones PW, Singh D, Bateman ED et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40:830-6.
18. Maltais F, Celli B, Casaburi R et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011; 105:580-7.
19. Alberti JJ, Sentellas S, Salva M. In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol. 2011; 81:761-76.
20. Alagha K, Bourdin A, Tummino C, Chanez P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Ther Adv Respir Dis. 2011; 5:19-28.
21. Vestbo J, Vogelmeier C, Creemers J et al. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010; 7:331-6.
22. Newman SP, Sutton DJ, Segarra R et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78:322-8.
23. Magnussen H, Watz H, Zimmerman I et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009; 103:1832-7.
24. Tudorza Pressair. In: Red Book Online. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically.